source
- FDA clears Lantheus' Tauklarify PET imaging agent for Alzheimer’s tau detectionLantheus received FDA clearance for its PET imaging agent Tauklarify, also known as MK-6240, which is designed to help diagnose Alzheimer’s disease by visualizing tau protein deposits. The clearan…
- Two undisclosed gene-therapy deaths raise doubts about China's fast-track trial pathwayTwo recent deaths in China’s early‑stage gene‑therapy trials have drawn international attention. Both patients suffered severe immune reactions after receiving high‑dose viral vector treatments, an…